NASDAQ · VYGR
Healthcare · Biotechnology
$2.46
Up+$0.01 (+0.41%)
Updated Oct 8, 2026, 12:32 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · VYGR
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
VYGR closed at $2.46 after 20 trading sessions, down 24.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $2.46 | $2.495 | $2.41 | $2.46 | 617.75K |
| Oct 5, 2026 | $2.43 | $2.55 | $2.39 | $2.46 | 1.39M |
| Oct 2, 2026 | $2.72 | $2.73 | $2.42 | $2.45 | 1.17M |
| Oct 1, 2026 | $2.67 | $2.75 | $2.63 | $2.675 | 600.09K |
| Sep 30, 2026 | $2.66 | $2.715 | $2.61 | $2.68 | 598.79K |
| Sep 29, 2026 | $2.70 | $2.70 | $2.58 | $2.64 | 628.61K |
| Sep 28, 2026 | $2.68 | $2.73 | $2.61 | $2.70 | 646.08K |
| Sep 25, 2026 | $2.78 | $2.79 | $2.64 | $2.68 | 721.3K |
| Sep 24, 2026 | $2.87 | $2.88 | $2.705 | $2.80 | 1.09M |
| Sep 23, 2026 | $3.14 | $3.14 | $2.87 | $2.87 | 690.92K |
| Sep 22, 2026 | $3.09 | $3.165 | $3.08 | $3.14 | 341.56K |
| Sep 21, 2026 | $3.13 | $3.155 | $3.05 | $3.08 | 292.67K |
| Sep 18, 2026 | $3.01 | $3.11 | $3.00 | $3.09 | 538.1K |
| Sep 17, 2026 | $3.05 | $3.112 | $3.00 | $3.04 | 681.16K |
| Sep 16, 2026 | $3.11 | $3.11 | $2.97 | $3.05 | 633.4K |
| Sep 15, 2026 | $3.19 | $3.19 | $3.03 | $3.09 | 452K |
| Sep 14, 2026 | $3.17 | $3.21 | $3.14 | $3.19 | 305.83K |
| Sep 11, 2026 | $3.24 | $3.28 | $3.145 | $3.19 | 276.06K |
| Sep 10, 2026 | $3.20 | $3.22 | $3.13 | $3.19 | 334.5K |
| Sep 9, 2026 | $3.37 | $3.38 | $3.205 | $3.25 | 500.58K |
The latest Smart Investors Daily articles mentioning VYGR.
Company
Market Activity
Research & News
VYGR research
Company profile and research snapshot.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 17, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 12, 2025 | HC Wainwright & Co. | Buy | — |
| Sep 15, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2025 | Wedbush | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
Voyager Therapeutics, Inc. (VYGR) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 3:45 PM EDTCompany ParticipantsAlfred Sandrock -...
Yahoo · Sep 1, 2026
LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Fireside chat at 3:45 p.m. ET on Tuesday, September 8, 2026, in Boston, MA.2026 Cantor Global Healthcare Conference: Fireside chat at 8:35 a.m. ET on Friday, September 11
Benzinga · Aug 10, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $25 price target.
Benzinga · Aug 6, 2026
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 29.82 percent increase over losses of $(0.57) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VYGR.
